MX2019011717A - Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. - Google Patents

Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.

Info

Publication number
MX2019011717A
MX2019011717A MX2019011717A MX2019011717A MX2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A
Authority
MX
Mexico
Prior art keywords
beta
alpha
cscs
compositions
methods
Prior art date
Application number
MX2019011717A
Other languages
English (en)
Spanish (es)
Inventor
Cheresh David
Wettersten Hiromi
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2019011717A publication Critical patent/MX2019011717A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019011717A 2017-03-31 2018-03-30 Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. MX2019011717A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479768P 2017-03-31 2017-03-31
PCT/US2018/025470 WO2018183894A1 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Publications (1)

Publication Number Publication Date
MX2019011717A true MX2019011717A (es) 2019-12-16

Family

ID=63676868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011717A MX2019011717A (es) 2017-03-31 2018-03-30 Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.

Country Status (12)

Country Link
US (2) US20200109205A1 (https=)
EP (2) EP4353318A3 (https=)
JP (2) JP2020512978A (https=)
KR (1) KR102630070B1 (https=)
CN (1) CN110662559A (https=)
AU (1) AU2018243670B2 (https=)
BR (1) BR112019020451A2 (https=)
CA (1) CA3058458A1 (https=)
EA (1) EA201992326A1 (https=)
IL (1) IL269746A (https=)
MX (1) MX2019011717A (https=)
WO (1) WO2018183894A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557246B (zh) 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
MX2022013207A (es) * 2020-04-23 2023-01-24 Alpha Beta Holdings Llc Metodos y composiciones para el tratamiento de cancer.
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
PT951295E (pt) * 1996-05-31 2010-07-29 Scripps Research Inst COMPOSIÎES PARA UTILIZAÆO NA INIBIÆO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1005327A1 (en) 1997-07-02 2000-06-07 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
HU229520B1 (en) * 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
EP1563832A1 (en) 1999-04-23 2005-08-17 Mitsubishi Chemical Corporation Liposome comprising a compound containing 2 polyalkylene glycol groups
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20080088046A1 (en) 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP2298308B1 (en) * 2005-11-14 2013-01-16 University Of Southern California Integrin-binding small molecules
US20080089928A1 (en) 2006-06-13 2008-04-17 Stavroula Sofou Liposome drug carriers with ph-sensitivity
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US20140154264A1 (en) * 2011-06-02 2014-06-05 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
AU2014331118B2 (en) * 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
TWI712421B (zh) * 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Also Published As

Publication number Publication date
EP3600422B1 (en) 2023-10-18
WO2018183894A1 (en) 2018-10-04
KR102630070B1 (ko) 2024-01-26
EP4353318A2 (en) 2024-04-17
EP3600422A4 (en) 2021-01-13
EA201992326A1 (ru) 2020-03-13
US20240067733A1 (en) 2024-02-29
AU2018243670B2 (en) 2025-05-01
BR112019020451A2 (pt) 2020-04-28
JP2020512978A (ja) 2020-04-30
CA3058458A1 (en) 2018-10-04
JP2021095423A (ja) 2021-06-24
AU2018243670A1 (en) 2019-10-31
KR20190133205A (ko) 2019-12-02
EP4353318A3 (en) 2024-07-17
CN110662559A (zh) 2020-01-07
IL269746A (en) 2019-11-28
US20200109205A1 (en) 2020-04-09
EP3600422A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
MX2019011717A (es) Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
MX2025015210A (es) Receptores de antigeno quimericos dirigidos a cd70
WO2018236870A3 (en) METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR
MX2024013525A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2025009209A (es) Anticuerpos de b7-h4 y metodos para usarlos
PH12022550509A1 (en) Anti-cd73 antibodies
ZA202405748B (en) Universal abt compounds and uses thereof
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MX2018014950A (es) Terapia de combinacion.
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
NZ812025A (en) Polypeptide variants and uses thereof
MY159837A (en) Therapeutic dll4 binding proteins
MY192146A (en) Binding molecules specific for asct2 and uses thereof
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
MX2018014863A (es) Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
WO2018213064A8 (en) Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
MX2024007390A (es) Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo.
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2017062615A3 (en) Combination therapy for the treatment of cancer
WO2023018722A3 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8